Literature DB >> 25583479

Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.

Chunzhang Yang1, Herui Wang2, Dongwang Zhu2, Christopher S Hong2, Pauline Dmitriev2, Chao Zhang2, Yan Li2, Barbara Ikejiri2, Roscoe O Brady1, Zhengping Zhuang1.   

Abstract

Gaucher disease is caused by mutations of the GBA1 gene, which encodes the lysosomal anchored gluococerebrosidase (GCase). GBA1 mutations commonly result in protein misfolding, abnormal chaperone recognition, and premature degradation, but are less likely to affect catalytic activity. In the present study, we demonstrate that the Hsp90/HOP/Cdc37 complex recruits Hsp27 after recognition of GCase mutants with subsequent targeting of GCase mutant peptides to degradation mechanisms such as VCP and the 26S proteasome. Inhibition of Hsp27 not only increased the quantity of enzyme but also enhanced GCase activity in fibroblasts derived from patients with Gaucher disease. These findings provide insight into a possible therapeutic strategy for protein misfolding diseases by correcting chaperone binding and altering subsequent downstream patterns of protein degradation.

Entities:  

Keywords:  Gaucher disease; heat shock protein; hsp27; hsp90; molecular chaperone

Mesh:

Substances:

Year:  2015        PMID: 25583479      PMCID: PMC4313839          DOI: 10.1073/pnas.1424288112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.

Authors:  Gholamreza Babajani; Michael B Tropak; Don J Mahuran; Allison R Kermode
Journal:  Mol Genet Metab       Date:  2012-04-26       Impact factor: 4.797

2.  Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry.

Authors:  Yuen Ho; Albrecht Gruhler; Adrian Heilbut; Gary D Bader; Lynda Moore; Sally-Lin Adams; Anna Millar; Paul Taylor; Keiryn Bennett; Kelly Boutilier; Lingyun Yang; Cheryl Wolting; Ian Donaldson; Søren Schandorff; Juanita Shewnarane; Mai Vo; Joanne Taggart; Marilyn Goudreault; Brenda Muskat; Cris Alfarano; Danielle Dewar; Zhen Lin; Katerina Michalickova; Andrew R Willems; Holly Sassi; Peter A Nielsen; Karina J Rasmussen; Jens R Andersen; Lene E Johansen; Lykke H Hansen; Hans Jespersen; Alexandre Podtelejnikov; Eva Nielsen; Janne Crawford; Vibeke Poulsen; Birgitte D Sørensen; Jesper Matthiesen; Ronald C Hendrickson; Frank Gleeson; Tony Pawson; Michael F Moran; Daniel Durocher; Matthias Mann; Christopher W V Hogue; Daniel Figeys; Mike Tyers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

Review 3.  Gaucher disease paradigm: from ERAD to comorbidity.

Authors:  Inna Bendikov-Bar; Mia Horowitz
Journal:  Hum Mutat       Date:  2012-06-11       Impact factor: 4.878

4.  ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.

Authors:  Yun Lei Tan; Joseph C Genereux; Sandra Pankow; Johannes M F G Aerts; John R Yates; Jeffery W Kelly
Journal:  Chem Biol       Date:  2014-08-14

5.  β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas.

Authors:  Chunzhang Yang; Rajiv R Iyer; Albert C H Yu; Raymund L Yong; Deric M Park; Robert J Weil; Barbara Ikejiri; Roscoe O Brady; Russell R Lonser; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-13       Impact factor: 11.205

Review 6.  Tanespimycin as antitumor therapy.

Authors:  Meletios-Athanassios Dimopoulos; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-02

7.  HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.

Authors:  Arnaud Parcellier; Elise Schmitt; Sandeep Gurbuxani; Daphné Seigneurin-Berny; Alena Pance; Aurélie Chantôme; Stéphanie Plenchette; Saadi Khochbin; Eric Solary; Carmen Garrido
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

8.  Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.

Authors:  Chunzhang Yang; Joey C Matro; Kristin M Huntoon; Donald Y Ye; Thanh T Huynh; Stephanie M J Fliedner; Jan Breza; Zhengping Zhuang; Karel Pacak
Journal:  FASEB J       Date:  2012-07-26       Impact factor: 5.191

Review 9.  Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.

Authors:  D R Ciocca; S Oesterreich; G C Chamness; W L McGuire; S A Fuqua
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

Review 10.  Mutations causing Gaucher disease.

Authors:  M Horowitz; A Zimran
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

View more
  10 in total

Review 1.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

Review 2.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

3.  Blockade of Glutathione Metabolism in IDH1-Mutated Glioma.

Authors:  Xiaoying Tang; Xiao Fu; Yang Liu; Di Yu; Sabrina J Cai; Chunzhang Yang
Journal:  Mol Cancer Ther       Date:  2019-09-23       Impact factor: 6.261

Review 4.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

Review 5.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

Review 6.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

7.  D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.

Authors:  Donghoon Kim; Heehong Hwang; Seulah Choi; Sang Ho Kwon; Suhyun Lee; Jae Hong Park; SangMin Kim; Han Seok Ko
Journal:  Acta Neuropathol Commun       Date:  2018-04-27       Impact factor: 7.801

8.  Mutant-selective topologic conversion facilitates selective degradation of a pathogenic prion isoform.

Authors:  Yumi Lee; Hongsik Eum; Duri Lee; Sohee Lee; Youngsup Song; Sang-Wook Kang
Journal:  Cell Death Differ       Date:  2019-05-24       Impact factor: 15.828

9.  Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma.

Authors:  Fengchao Lang; Abhishek Jha; Leah Meuter; Karel Pacak; Chunzhang Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-20       Impact factor: 6.055

10.  Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.

Authors:  Yang Liu; Ying Pang; Veronika Caisova; Jianyi Ding; Di Yu; Yiqiang Zhou; Thanh-Truc Huynh; Hans Ghayee; Karel Pacak; Chunzhang Yang
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.